Investor Presentaiton
Company overview
Financial performance
Oncology
Financial review
2022 priorities
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
Abbreviations
Immunology
Ophthalmology
Neuroscience
Respiratory Disease
Cardio-Renal
Global Health
Biosimilars
RydaptⓇ - Multi-targeted kinase inhibitor
NCT03591510 (CPKC412A2218)
Acute myeloid leukemia, pediatrics
Phase 2
Indication
Phase
Patients
20
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Occurrence of dose limiting toxicities
Safety and Tolerability
Chemotherapy followed by Midostaurin
Newly diagnosed pediatric patients with FLT3 mutated acute myeloid
leukemia (AML)
Read-out
Milestone(s)
2026
Publication
TBD
59 Investor Relations | Q2 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation